Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry

0544081 - ÚI 2022 RIV CH eng J - Článek v odborném periodiku
Boriani, G. - De Caterina, R. - Manu, M. C. - Souza, J. - Pecen, Ladislav - Kirchhof, P.
Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry.
Journal of Clinical Medicine. Roč. 10, č. 13 (2021), č. článku 2879. E-ISSN 2077-0383
Institucionální podpora: RVO:67985807
Klíčová slova: atrial fibrillation * edoxaban * weight * registry * effectiveness * safety * non-vitamin K antagonist oral anticoagulants * stroke
Obor OECD: Cardiac and Cardiovascular systems
Impakt faktor: 4.964, rok: 2021
Způsob publikování: Open access
http://dx.doi.org/10.3390/jcm10132879

Background: Extremes of body weight may alter exposure to non-vitamin K antagonist oral anticoagulants and thereby impact clinical outcomes. This ETNA-AF-Europe sub-analysis assessed 1-year outcomes in routine care patients with atrial fibrillation across a range of body weight groups treated with edoxaban. Methods: ETNA-AF-Europe is a multinational, multicentre, observational study conducted in 825 sites in 10 European countries. Overall, 1310, 5565, 4346 and 1446 enrolled patients were categorised into <= 60 kg, >60-<= 80 kg (reference weight group), >80-<= 100 kg and >100 kg groups. Results: Patients weighing <= 60 kg were older, more frail and had a higher CHA(2)DS(2)-VASc score vs. the other weight groups. The rates of stroke/systemic embolism, major bleeding and ICH were low at 1 year (0.82, 1.05 and 0.24%/year), with no significant differences among weight groups. The annualised event rates of all-cause death were 3.50%/year in the overall population. After adjustment for eGFR and CHA(2)DS(2)-VASc score, the risk of all-cause death was significantly higher in extreme weight groups vs. the reference group. Conclusions: Low rates of stroke and bleeding were reported with edoxaban, independent of weight. The risk of all-cause death was higher in extremes of weight vs. the reference group after adjustment for important risk modifiers, thus no obesity paradox was observed.
Trvalý link: http://hdl.handle.net/11104/0321140